6 results
The main objective of this study is to test the effects of combined SGLT1 and SGLT2 inhibition with sotagliflozin on hemoconcentration and plasma volume in patients with heart failure.
Main goal is to gain more insight in the role of dopaminergic neurotransmission in rewards, motivation and the attribution of salience in the etiology of psychosis. Primary question is whether a change in blood oxygation level dependent (BOLD) fMRI…
The first objective is measuring striatal D2 receptor binding before and after dopamine depletion with AMPT in the UHR population compared to healthy controls, and investigate whether dopaminergic dysregulation is present prior to transition to…
The main objectives of the study are to demonstrate whether sotagliflozin reduces the composite of CV (cardiovascular) death and HHF (hospitalization for heart failure) as compared to placebo in diabetic patients after admission for WHF (worsening…
This study is designed to demonstrate the CV and renal effects of sotagliflozin in patients with T2D, high CV risk, and moderate renal impairment. One of the major objectives of this study is to fulfill the regulatory mandate that any new therapy…
Proof of Principle: to assess feasibility to measure; (1) a reproducible 1st thermal IDC, (2) at least 1 recirculation IDC using the FBG photonic sensor both peripheral and nasal. - to compare the acquired Stroke Volume (SV) and Cardiac Output (CO)…